Levonic-Opto (Levofloxacin)

Levofloxacin blocks bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. This inhibition stops bacterial cell division, leading to rapid bactericidal activity against a broad spectrum of ocular pathogens.

The dosing regimen for Levonic-Opto is determined by the prescribing ophthalmologist based on the severity of the infection, the specific pathogen, and patient factors. The prescriber will provide exact instructions for frequency and duration of use.

Safety data for Levonic-Opto in pregnancy and lactation are limited. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by the treating physician.

To order Levonic-Opto, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Levonics-Opto belongs to the fluoroquinolone class, offering broad‑spectrum coverage against many Gram‑positive and Gram‑negative bacteria. Compared with older agents such as chloramphenicol or polymyxin‑B/trimethoprim, levofloxacin often provides faster bacterial eradication and a lower risk of resistance development, though individual choice depends on susceptibility patterns and patient tolerance.

Levonics-Opto should be stored at room temperature, below 25 °C, in its original container. Keep the bottle tightly closed, protect it from direct light and moisture, and discard any solution that appears discolored or contains particles.

Levonics-Opto is applied topically to the eye as directed by the prescriber. Typically, a few drops are instilled into the affected eye(s) at the prescribed frequency, with hands washed beforehand and contact lenses removed before administration.

Serious adverse events include severe allergic reactions (anaphylaxis, angioedema), tendon rupture, Stevens‑Johnson syndrome, toxic epidermal necrolysis, corneal ulceration or perforation, and systemic QT‑interval prolongation. Patients should seek immediate medical attention if they experience symptoms such as swelling, rash, vision changes, or severe pain.

Levonics-Opto should be avoided in individuals with known hypersensitivity to levofloxacin, other fluoroquinolones, or any component of the formulation. Caution is also advised for patients with a history of tendon disorders, uncontrolled epilepsy, or those receiving concurrent systemic fluoroquinolones.